64 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
A FRET-Based Assay for the Identification and Characterization of Cereblon Ligands.
Max Planck Institute For Developmental Biology
Recent advance of small-molecule drugs for clinical treatment of multiple myeloma.
Jilin University
Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9.
University of Michigan
Revisiting the antiangiogenic mechanisms of fluorinated thalidomide derivatives.
University of Bonn
Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression.
University of Michigan
Discovery of Novel Potent and Fast BTK PROTACs for the Treatment of Osteoclasts-Related Inflammatory Diseases.
The People's Hospital of Guangxi Zhuang Autonomous Region & Guangxi Academy of Medical Sciences
Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell Lymphoma.
Kymera Therapeutics
Discovery and characterization of potent spiro-isoxazole-based cereblon ligands with a novel binding mode.
Saint Petersburg State University
Discovery of a Promising CBP/p300 Degrader XYD129 for the Treatment of Acute Myeloid Leukemia.
Shenyang Pharmaceutical University
Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update.
Eberhard Karls University Tubingen
Facilitating the development of molecular glues: Opportunities from serendipity and rational design.
Sichuan University
Discovery of Novel Proteolysis-Targeting Chimera Molecules as Degraders of Programmed Cell Death-Ligand 1 for Breast Cancer Therapy.
Sichuan University
Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity
University of Michigan
Development of sulfonyl fluoride chemical probes to advance the discovery of cereblon modulators.
Dana-Farber Cancer Institute
One-Pot Synthesis of Cereblon Proteolysis Targeting Chimeras via Photoinduced C(sp
Boehringer Ingelheim Rcv
Covalent Stapling of the Cereblon Sensor Loop Histidine Using Sulfur-Heterocycle Exchange.
Dana-Farber Cancer Institute
Leveraging Ligand Affinity and Properties: Discovery of Novel Benzamide-Type Cereblon Binders for the Design of PROTACs.
University of Bonn
Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer.
University of Michigan
Synthesis of novel glutarimide ligands for the E3 ligase substrate receptor Cereblon (CRBN): Investigation of their binding mode and antiproliferative effects against myeloma cell lines.
Saint Petersburg State University
Developments of PROTACs technology in immune-related diseases.
The Affiliated Hospital of Qingdao University
Discovery of Novel Bruton's Tyrosine Kinase PROTACs with Enhanced Selectivity and Cellular Efficacy.
Stony Brook University
E3 Ligases Meet Their Match: Fragment-Based Approaches to Discover New E3 Ligands and to Unravel E3 Biology.
Astrazeneca
Structural rationalization of GSPT1 and IKZF1 degradation by thalidomide molecular glue derivatives.
Dana-Farber Cancer Institute
A comprehensive review of BET-targeting PROTACs for cancer therapy.
Xinxiang Medical University
Developments of CRBN-based PROTACs as potential therapeutic agents.
The Affiliated Hospital of Qingdao University
Homobivalent, Trivalent, and Covalent PROTACs: Emerging Strategies for Protein Degradation.
Second Military Medical University
Development of Potent and Selective Janus Kinase 2/3 Directing PG-PROTACs.
St. Jude Children'S Research Hospital
A biphenyl inhibitor of eIF4E targeting an internal binding site enables the design of cell-permeable PROTAC-degraders.
Dana-Farber Cancer Institute
Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 Pseudokinase.
Astrazeneca
Sweet and Blind Spots in E3 Ligase Ligand Space Revealed by a Thermophoresis-Based Assay.
Max Planck Institute For Developmental Biology
Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
Shaoxing University
Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders.
TBA
NOVEL INHIBITORS OF GUANOSINE MONOPHOSPHATE SYNTHETASE AS THERAPEUTIC AGENTS
University of Southern California
CDK12/13 COVALENT INHIBITORS OR PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF
University of Michigan
SULFONYLPIPERAZINYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS
Hoffmann-La Roche
Disubstituted Pyrimidine Compounds for Ketohexokinase Inhibition
Centennial Therapeutics
ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF
1Cbio
NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
Shanghai Hansoh Biomedical
Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis
Novartis
Small molecule modulators of pantothenate kinases
St. Jude Children'S Research Hospital
Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5)
Prelude Therapeutics
Thieno[3,2-d]pyrimidine derivative compound having inhibitory activity for protein kinase
Hanmi Pharm.